【摘要】 【目的】观察维生素K滴剂-Orakay(凯欧凯)口服对改善新生儿的维生素K营养状况的结果。【方法】将84例新生儿分为试验组59例(出生后口服Orakay1mg)和对照组25例(未用Orakay),于6~7d时检测血循环中凝血酶原前体蛋白(PIVKA-Ⅱ)含量。【结果】生后24h内,59例试验组新生儿中,17例可检测到PIVKA-Ⅱ,阳性率为28.81％。服用Orakay(凯欧凯)后,第7d时17例PIVKA-Ⅱ阳性的新生儿全部变为阴性。25例对照组新生儿,6d时10例可检测到凝血酶原前体蛋白(PIVKA-Ⅱ),阳性率为40％。【结论】出生24h内口服1mgOrakay一次,能保证小儿7d时不出现亚临床维生素K缺乏。更多还原

【Abstract】 [Objective] To observe the effect of oral Orakay for improving their vitamin K deficiency status in newborns. [Methods] 84 newborns were divided into Orakay group (59 cases) and control group (25 cases). All newborns of Orakay group were administered to Orakay 1 mg in 24 hours after birth. At 6-7th day, these newborns were determined in PIVKA-Ⅱ. [Results] In Orakay group, 17 out of 59 were positive in PIVKA-Ⅱ in 24 hours after birth, the positive rate was 28. 81%. At 7th day,all of 59 cases were negative in PIVKA-Ⅱ. At 6th day, 10 out of 25 in control group were still positive PIVKA-Ⅱ, the positive rate was 40%. [Conclusion] 1 mg Orakay in 24 hours after birth can prevent newborns from vitamin K deficiency.更多还原